• 1
    Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778809.
  • 2
    Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000–05 update. Ann Pharmacother 2006; 40:7482.
  • 3
    Ward RP, Kugelmas M. Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician 2005; 72:65562.
  • 4
    Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alpha-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005; 52:9115.
  • 5
    Goodin DS. Treatment of multiple sclerosis with human beta interferon. Int MS J 2005; 12:96108.
  • 6
    Kracke A, Von Wussow P, Al-Masri AN, Dalley G, Windhagen A, Heidenreich F. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000; 54:1939.
  • 7
    Chieux V, Chehadeh W, Hautecoeur P, Harvey J, Wattre P, Hober D. Increased levels of antiviral MxA protein in peripheral blood of patients with a chronic disease of unknown etiology. J Med Virol 2001; 65:3018.
  • 8
    Bagnato F, Pozzilli C, Scagnolari C et al. A one-year study on the pharmacodynamic profile of interferon-beta1a in MS. Neurology 2002; 58:140911.
  • 9
    Scagnolari C, Casato M, Bellomi F et al. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Clin Diagn Lab Immunol 2003; 10:707.
  • 10
    Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFN beta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003; 61 (Suppl 5):S246.
  • 11
    Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Capobianco M, Bertolotto A. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 2006; 12:4757.
  • 12
    Della Rossa A, Tavoni A, Baldini C, Bombardieri S. Treatment of chronic hepatitis C infection with cryoglobulinemia. Curr Opin Rheumatol 2002; 14:2317.
  • 13
    Chieux V, Hober D, Harvey J et al. The MxA protein levels in whole blood lysates of patients with various viral infections. J Virol Meth 1998; 70:18391.
  • 14
    MacQuillan GC, De Boer WB, Platten MA et al. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. J Med Virol 2002; 68:197205.
  • 15
    MacQuillan GC, Mamotte C, Reed WD, Jeffrey GP, Allan JE. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol 2003; 70:21927.
  • 16
    Gerotto M, Dal Pero F, Bortoletto G et al. PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C. Antivir Ther 2004; 9:76370.
  • 17
    Bagnato F, Durastanti V, Finamore L, Volante G, Millefiorini E. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis. Neurol Sci 2003; 24:S3014.
  • 18
    Saadoun D, Boyer O, Trebeden-Negre H et al. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol 2004; 41:10317.
  • 19
    Hamerlinck FF. Neopterin: a review. Exp Dermatol 1999; 8:16776.
  • 20
    Ichikawa T, Nakao K, Nakata K et al. Involvement of IL-1beta and IL-10 in IFN-alpha-mediated antiviral gene induction in human hepatoma cells. Biochem Biophys Res Commun 2002; 294:41422.
  • 21
    Haahr S, Moller-Larsen A, Justesen J, Pedersen E. Interferon induction, 2′−5′ oligo A synthetase and lymphocyte subpopulations in out-patients with multiple sclerosis in a longitudinal study. Acta Neurol Scand 1986; 73:34551.
  • 22
    Schattner A, Merlin G, Bregman V et al. (2′-5′) Oligo A synthetase in human polymorphonuclear cells increased activity in interferon treatment and in viral infections. Clin Exp Immunol 1984; 57:26570.
  • 23
    Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002; 129:20515.
  • 24
    Cook SD. Does Epstein–Barr virus cause multiple sclerosis? Rev Neurol Dis 2004; 1:11523.
  • 25
    Lutton JD, Winston R, Rodman TC. Multiple sclerosis: etiological mechanisms and future directions. Exp Biol Med 2004; 229:1220.
  • 26
    Kamin-Lewis RM, Panitch HS, Merigan TC, Johnson KP. Decreased interferon synthesis and responsiveness to interferon by leukocytes from multiple sclerosis patients given natural alpha interferon. J Interferon Res 1984; 4:42332.
  • 27
    Dettke M, Scheidt P, Prange H, Kirchner H. Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. J Clin Immunol 1997; 17:293300.
  • 28
    Hertzog PJ, Wright A, Harris G, Linnane AW, Mackay IR. Intermittent interferonemia and interferon responses in multiple sclerosis. Clin Immunol Immunopathol 1991; 58:1832.
  • 29
    Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78:31823.
  • 30
    Antonelli G, Simeoni E, Turriziani O et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 1999; 19:24351.
  • 31
    Fernandez M, Quiroga JA, Martin J et al. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J Infect Dis 1999; 180:2627.
  • 32
    Bagnato F, Durastanti V, Finamore L, Volante G, Millefiorini E. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis. Neurol Sci 2003; 24 (Suppl. 5):S3014.
  • 33
    Giannelli G, Guadagnino G, Dentico P, Antonelli G, Antonaci S. MxA and PKR expression in chronic hepatitis C. J Interferon Cytokine Res 2004; 24:65963.